Table 2

Mean changes in glycemic control parameters between baseline and week 12

Change from baselineComparison to placebo at week 12
Placebo
(n=16)
WBF-010
(n=21)
WBF-011
(n=21)
WBF-010WBF-011
MeanP valueMeanP value
Total glucose AUC0-180
(mg/dL/180 min)
21.2±14.711.2±8.5−14.9±13.8−10.00.5810
(0.1270*)
−36.10.0500
(0.0143*)
A1c (%)0.4±0.20.2±0.2−0.2±0.2−0.20.4684−0.60.0540
Fasting plasma glucose (mg/dL)2.8±10.814.8±7.5−3.0±11.212.00.4099−5.80.6890
Incremental glucose AUC0-180
(mg/dL/180 min)
16.9±7.4−3.6±6.1−11.7±7.2−20.40.0482−28.60.0066
Total insulin AUC0-180
(µIU/mL/180 min)
−2.2±4.6−2.9±2.94.4±4.5−0.70.90706.60.2718
Incremental insulin AUC0-180
(µIU/mL/180 min)
−3.3±4.4−2.0±2.71.5±4.01.30.81974.80.3825
HOMA-IR0.8±0.7−0.1±0.70.8±0.6−0.90.40880.00.9782
  • See model estimates in online supplementary figure S6 and Methods section for further details.

  • *P values from the stepwise-selected model defined in the Statistical Analysis Plan (online supplementary text S2).

  • AUC, area under the curve; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance.